Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Abstract 2207: A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM)., Cancer Research, April 2013, American Association for Cancer Research (AACR),
DOI: 10.1158/1538-7445.am2013-2207.
You can read the full text:
Contributors
The following have contributed to this page
